154 related articles for article (PubMed ID: 30592722)
1. The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer.
Wong K; Ozeki K; Kwong A; Patel BN; Kwo P
PLoS One; 2018; 13(12):e0208233. PubMed ID: 30592722
[TBL] [Abstract][Full Text] [Related]
2. Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.
Wei J; Li H; Li C
J Cancer Res Ther; 2018; 14(4):826-832. PubMed ID: 29970660
[TBL] [Abstract][Full Text] [Related]
3. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
[TBL] [Abstract][Full Text] [Related]
5. Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts.
Park JK; Al-Tariq QZ; Zaw TM; Raman SS; Lu DS
Cardiovasc Intervent Radiol; 2015 Oct; 38(5):1211-7. PubMed ID: 25670215
[TBL] [Abstract][Full Text] [Related]
6. Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS).
Chang J; Dumitrache A; Böhling N; Abu-Omar J; Meyer C; Strobel D; Luetkens J; Luu AM; Rockstroh J; Strassburg CP; Trebicka J; Gonzalez-Carmona MA; Marinova M; Praktiknjo M
Sci Rep; 2020 Nov; 10(1):20682. PubMed ID: 33244180
[TBL] [Abstract][Full Text] [Related]
7. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Qiu B; Li K; Dong X; Liu FQ
Cardiovasc Intervent Radiol; 2017 Sep; 40(9):1372-1382. PubMed ID: 28488102
[TBL] [Abstract][Full Text] [Related]
8. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Treating Portal Hypertension in Patients with Hepatocellular Carcinoma.
Balducci D; Montori M; De Blasio F; Di Bucchianico A; Argenziano ME; Baroni GS; Scarpellini E
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374354
[TBL] [Abstract][Full Text] [Related]
9. Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review.
Norero B; Bosch J; Berzigotti A; Rodrigues SG
United European Gastroenterol J; 2023 Oct; 11(8):733-744. PubMed ID: 37736854
[TBL] [Abstract][Full Text] [Related]
10. Occult Hepatocellular Carcinoma Associated With Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant Recipients.
Krumeich LN; Mancinelli J; Cucchiara A; Eddinger K; Aufhauser D; Goldberg DW; Siegelman ES; Rosen M; Reddy KR; Hoteit M; Furth EE; Olthoff KM; Shaked A; Levine M; Abt P
Liver Transpl; 2021 Sep; 27(9):1248-1261. PubMed ID: 33853207
[TBL] [Abstract][Full Text] [Related]
11. Long-term observation after transjugular intrahepatic portosystemic stent-shunt in two patients with hepatocellular carcinoma.
Tazawa J; Sakai Y; Yamane M; Kakinuma S; Maeda M; Suzuki K; Miyasaka Y; Nagayama K; Kusano F; Sato C
J Clin Gastroenterol; 2000 Oct; 31(3):262-7. PubMed ID: 11034013
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma.
Bettinger D; Knüppel E; Euringer W; Spangenberg HC; Rössle M; Thimme R; Schultheiß M
Aliment Pharmacol Ther; 2015 Jan; 41(1):126-36. PubMed ID: 25329493
[TBL] [Abstract][Full Text] [Related]
13. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
Luo SH; Chu JG; Huang H; Zhao GR; Yao KC
World J Gastroenterol; 2019 Mar; 25(9):1088-1099. PubMed ID: 30862997
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts.
Tesdal IK; Wikström M; Flechtenmacher C; Filser T; Dueber C
Cardiovasc Intervent Radiol; 2006; 29(5):778-84. PubMed ID: 16779690
[TBL] [Abstract][Full Text] [Related]
15. Trans-jugular intrahepatic portosystemic shunt in patients with hepatic cellular carcinoma: A preliminary study.
Dong H; Zhang C; Li Z; Yang H; Wang Y; Liu J; Liu B; Mao S
J Cancer Res Ther; 2021 Jul; 17(3):784-789. PubMed ID: 34269314
[TBL] [Abstract][Full Text] [Related]
16. Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis.
Jiang ZB; Shan H; Shen XY; Huang MS; Li ZR; Zhu KS; Guan SH
World J Gastroenterol; 2004 Jul; 10(13):1881-4. PubMed ID: 15222028
[TBL] [Abstract][Full Text] [Related]
17. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
[TBL] [Abstract][Full Text] [Related]
18. Transjugular intrahepatic portosystemic shunt creation for cirrhotic portal hypertension is well tolerated among patients with portal vein thrombosis.
Merola J; Fortune BE; Deng Y; Ciarleglio M; Amirbekian S; Chaudhary N; Shanbhogue A; Ayyagari R; Rodriguez-Davalos MI; Teperman L; Charles HW; Sigal SH
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):668-675. PubMed ID: 29462027
[TBL] [Abstract][Full Text] [Related]
19. Cirrhotic patients with a transjugular intrahepatic portosystemic shunt undergoing major extrahepatic surgery.
Kim JJ; Dasika NL; Yu E; Fontana RJ
J Clin Gastroenterol; 2009 Jul; 43(6):574-9. PubMed ID: 19169145
[TBL] [Abstract][Full Text] [Related]
20. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
